Corona Remedies IPO Opens: Key Details & Strong GMP
Corona Remedies IPO subscription starts Dec 8. Price band ₹1008-1062, aims to raise ₹655 cr. Grey market premium signals strong investor interest. Details inside.
Category : Search result: Purdue Pharma bankruptcy
Corona Remedies IPO Subscription Begins, GMP at ₹290
Corona Remedies' ₹655 crore IPO opens today. With a price band of ₹1,008-₹1,062 and a strong GMP, analysts give a 'Subscribe for long term' rating. Key dates and details inside.
Odisha Approves Pharma & Medtech Policy 2025
Odisha's new Pharma & Medtech Policy 2025 aims to make the state a strategic hub for healthcare manufacturing. The policy includes plans for dedicated industrial parks and a roadmap aligned with India's 2047 vision. Read more.
When Amitabh Bachchan Called Director Asking for Work
Director Suneel Darshan reveals how Amitabh Bachchan personally called him for a role during his 90s financial crisis and worked punishing double shifts for the film Ek Rishta. Read the inspiring story.
Himachal Pharma Sector Faces Major Trust Crisis
Himachal Pradesh's pharmaceutical hub is in turmoil as 38 firms lose WHO-GMP certification, raising serious quality concerns. Discover the causes and impact.
Canacol Energy in Debt Talks as Cash Reserves Dwindle
Colombia's top private gas producer, Canacol Energy, negotiates emergency financing to restructure debt as output declines. Will creditors agree? Full details inside.
Shilo Sanders Faces $250K NIL Transfer Allegations in Bankruptcy
NFL free agent Shilo Sanders, son of Deion Sanders, faces allegations of unauthorized $250,000 transfers from NIL deals amid Chapter 7 bankruptcy. His attorney disputes the claims, setting a potential precedent for athlete finances.
Nivin Pauly's 'Pharma' Trailer Targets Unethical Drug Practices
Nivin Pauly's OTT debut 'Pharma' trailer reveals a medical rep exposing dangerous drugs. The series premieres on JioCinema December 19 in 7 languages. Read more.
Bronx Affordable Housing Project Files Chapter 11 Bankruptcy
Dynamic Star LLC, owner of Bronx's Fordham Landing, files Chapter 11 to halt foreclosure. $55M state funding for 900 affordable units now under review. Read the latest on this major NYC housing development.
Laurus Labs aims for 50% revenue from CDMO business in 5 years
Hyderabad's Laurus Labs plans aggressive CDMO growth, targeting 50% of revenue in five years. CEO Dr. Satyanarayana Chava reveals strategy focusing on cell & gene therapy and global expansion. Read more.
Granules India's US facility passes FDA GMP inspection
Granules India's US subsidiary, Granules Consumer Health LLC, successfully cleared a USFDA GMP inspection with zero observations. This marks a significant achievement for the Hyderabad-based pharma major's OTC product operations in America.
Corona Remedies IPO: Key Dates, Price Band, Details
Corona Remedies IPO opens Dec 8, 2025, to raise ₹655.37 crore. Check price band, GMP, financials, and key dates for this pharma company's public issue.
Market Opens Strong: Nifty Above 25,400, Gift Nifty Up
Indian stock markets opened strong on December 3, 2025, with Nifty crossing 25,400. Key stocks like TCS and Sun Pharma in focus. Read for full analysis and trading cues.
Wockhardt Shares Jump 6% on USFDA NDA Acceptance for Zaynich
Wockhardt's share price surged over 6% after the USFDA accepted its New Drug Application for Zaynich, a novel antibiotic. Discover the details and market impact.
iRobot's $191M Debt Sold to Supplier Amid Bankruptcy Risk
Carlyle Group sells troubled iRobot loan to Chinese supplier Santrum. The Roomba maker warns of potential bankruptcy without new capital. Read the full analysis.
Ex-Corporator Warns of Bankruptcy for Bengaluru Civic Bodies
Former corporator N R Ramesh warns Bengaluru's GBA and new civic bodies risk bankruptcy, citing a revenue gap. Property tax collection stands at only Rs 4,500 crore. Read the full analysis.
Sun Pharma's Ilumya for Psoriasis Launched in India
Sun Pharma introduces its global biologic Ilumya for moderate-to-severe plaque psoriasis in India. Backed by Phase-3 data, it offers long-lasting clearance with a strong safety profile. Learn more about this targeted therapy.
Realty IBC Reforms Pushed to Later Phase
Government to introduce corporate IBC amendments first, delaying structural reforms for homebuyers and stuck projects. Key changes for real estate require further consultation. #IBC #RealEstate
Anupam Kher: From Rs 400 to Rs 3 Crore Per Film
Anupam Kher reveals how he faced near bankruptcy with only Rs 400 in bank, mortgaged properties, and made remarkable comeback charging Rs 3 crore per film. Read his inspiring story.
India's Bulk Drug Makers Ramp Up CDMO Investments
Indian API manufacturers are shifting to high-value contract development, targeting $22-25 billion market by 2035 as global pharma diversifies from China. Read about the growth trajectory.
Jaiprakash Gaur's Legacy Ends in Bankruptcy
At 94, Jaiprakash Gaur watches his life's work collapse as NCLT admits Jaiprakash Associates into insolvency. Read about his rags-to-riches story and ultimate downfall.
Pharma Chemical Firms Outperform with 7% Growth
Speciality chemical makers supplying pharma CDMOs post 7% sales growth, outpacing non-pharma peers. Strong margins and global shifts fuel this resilient sector. Read more.
Financial creditors surpass operational creditors in IBC cases
India's insolvency code undergoes significant shift as financial creditors now dominate bankruptcy proceedings. Analysis reveals changing creditor behavior and recovery patterns under IBC framework since 2020 threshold change.
November 2025 IPO Analysis: Market Trends Revealed
November 2025 witnessed 9 IPOs with 12 listings. Groww leads with 58.85% gains while experts warn of investor fatigue and unrealistic valuations. Read full analysis.
Sudeep Pharma Shares Jump 33% After Strong IPO Listing
Sudeep Pharma shares surged 33.78% in market debut, exceeding expectations. Analysts advise partial profit booking while maintaining long-term optimism. Read expert views on buy/sell strategy.
Sudeep Pharma IPO Lists at 23% Premium on NSE, BSE
Sudeep Pharma shares surged 23% in stock market debut today, outperforming grey market expectations. The ₹895-crore IPO was subscribed 93.71 times. Read full analysis.
Sudeep Pharma IPO Lists on BSE, NSE Today
Sudeep Pharma makes its stock market debut today. With a GMP of ₹121, the IPO is set for 20% listing gains after a blockbuster 93.72 times subscription. Get all the live details.
Sudeep Pharma IPO Lists Today with Strong Grey Market Premium
Sudeep Pharma shares list on BSE and NSE today after 93.72 times subscription. Grey market signals 20% premium debut. Full details on pricing and investor response.
IBC Reforms: Biggest Changes in 9 Years Coming
India's Insolvency and Bankruptcy Code undergoes major reforms with cross-border insolvency and faster debt resolution. Parliament to consider revised bill in December session.
Sudeep Pharma IPO Listing on Nov 28 with Strong GMP
Sudeep Pharma IPO makes Dalal Street debut on November 28. Grey market premium hits ₹100, signaling 15% listing gain. Discover subscription details and key facts.
Page 1 of 4